Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

Albert Parés1, Llorenç Caballería, Juan Rodés

  • 1Liver Unit, Digestive Diseases Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain. pares@ub.edu

Gastroenterology
|March 15, 2006

Related Experiment Videos

View abstract on PubMed

Summary
This summary is machine-generated.

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Excellent Long-term Survival In Patients With Primary Biliary Cirrhosis And Biochemical Response To Ursodeoxycholic Acid.

    • Ursodeoxycholic acid (UDCA) treatment improves survival in primary biliary cirrhosis (PBC) patients. Achieving a biochemical response to UDCA within one year is linked to survival comparable to the general population.

    Area of Science:

    • Hepatology
    • Clinical Medicine
    • Pharmacology

    Background:

    • Long-term efficacy of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) requires further elucidation.
    • Assessing UDCA's impact on PBC patient outcomes and survival is crucial.

    Purpose of the Study:

    • To evaluate the long-term course and survival of PBC patients treated with UDCA.
    • To compare patient survival with predictions from the Mayo model and a standardized population.

    Main Methods:

    • 192 PBC patients (181 women) received UDCA (15 mg/kg/day) for 1.5-14 years.
    • Treatment response defined by >40% alkaline phosphatase decrease or normalization after 1 year.
    • Survival data compared against Mayo model predictions and a matched Spanish population.

    Main Results:

    • Observed survival was higher than Mayo model predictions but lower than the control population (P < .001).
    • 61% of patients responded to UDCA treatment.
    • Responders showed significantly better survival than predicted by the Mayo model and similar survival to the control population (P = .15).
    • Non-responders had lower survival than the Spanish population (P < .001) but better than the Mayo model.

    Conclusions:

    • Biochemical response to UDCA after one year correlates with survival similar to the general population, supporting UDCA's benefits in PBC.
    • Suboptimal survival in non-responders highlights a group needing further therapeutic strategies.

    Related Experiment Videos